This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Roche’s CT-388 Dual GLP-1/GIP Agonist Phase II Obesity Results
Ticker(s): RHHBYWho's the expert?
Institution: Stanford
- Professor of Endocrinology at Stanford
- Manages hundreds of patients for obesity and type 2 diabetes
- Research interest in the role of incretin hormones in glucose metabolism and postbariatric hypoglycemia and the use of continuous glucose monitoring
Interview GoalTo gain a deeper understanding of Roche’s CT-388 Dual GLP-1/GIP Agonist as a potential treatment for obesity
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
